Burning Rock Biotech (NASDAQ:BNR) Director Purchases $5,466,143.20 in Stock

Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) Director Yusheng Han purchased 314,870 shares of the business’s stock in a transaction dated Tuesday, March 31st. The shares were acquired at an average price of $17.36 per share, for a total transaction of $5,466,143.20. Following the acquisition, the director owned 17,672,676 shares of the company’s stock, valued at $306,797,655.36. This trade represents a 1.81% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Burning Rock Biotech Price Performance

Shares of Burning Rock Biotech stock traded up $0.14 during trading on Thursday, hitting $16.44. The company’s stock had a trading volume of 22,992 shares, compared to its average volume of 28,586. The stock has a market cap of $176.86 million, a price-to-earnings ratio of -20.80 and a beta of 1.35. Burning Rock Biotech Limited Sponsored ADR has a 52 week low of $2.18 and a 52 week high of $41.72. The stock has a 50-day moving average price of $26.13 and a two-hundred day moving average price of $19.41.

Burning Rock Biotech (NASDAQ:BNR) last announced its earnings results on Saturday, February 14th. The company reported ($0.21) EPS for the quarter. Burning Rock Biotech had a negative return on equity of 9.98% and a negative net margin of 10.27%.The company had revenue of $18.05 million for the quarter.

Hedge Funds Weigh In On Burning Rock Biotech

Several institutional investors have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Burning Rock Biotech during the 3rd quarter worth approximately $26,000. Marshall Wace LLP bought a new position in Burning Rock Biotech during the fourth quarter worth $220,000. Prospera Financial Services Inc bought a new position in Burning Rock Biotech during the third quarter worth $214,000. Finally, Crcm LP grew its holdings in Burning Rock Biotech by 13.8% in the third quarter. Crcm LP now owns 221,575 shares of the company’s stock worth $1,917,000 after purchasing an additional 26,809 shares during the period. 30.03% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on BNR shares. Wall Street Zen upgraded shares of Burning Rock Biotech from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Burning Rock Biotech in a research report on Wednesday, January 21st. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Burning Rock Biotech presently has an average rating of “Sell”.

About Burning Rock Biotech

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.